BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $743 | -35.9% | 19,682 | -22.6% | 0.00% | -40.0% |
| Q2 2023 | $1,159 | +12.5% | 25,437 | +0.2% | 0.01% | 0.0% |
| Q1 2023 | $1,030 | -38.2% | 25,394 | -22.3% | 0.01% | -37.5% |
| Q4 2022 | $1,666 | -99.9% | 32,695 | +12.8% | 0.01% | -11.1% |
| Q3 2022 | $1,561,000 | -18.4% | 28,984 | -2.7% | 0.01% | -25.0% |
| Q2 2022 | $1,913,000 | -23.5% | 29,777 | -7.7% | 0.01% | -20.0% |
| Q1 2022 | $2,502,000 | -4.6% | 32,268 | +5.6% | 0.02% | -6.2% |
| Q4 2021 | $2,624,000 | +27.4% | 30,567 | +19.3% | 0.02% | +14.3% |
| Q3 2021 | $2,060,000 | -1.9% | 25,615 | -1.8% | 0.01% | -12.5% |
| Q2 2021 | $2,100,000 | +11.8% | 26,087 | +17.2% | 0.02% | -5.9% |
| Q1 2021 | $1,878,000 | -5.6% | 22,263 | -10.2% | 0.02% | -32.0% |
| Q4 2020 | $1,990,000 | -26.1% | 24,801 | -26.0% | 0.02% | -39.0% |
| Q3 2020 | $2,694,000 | -13.4% | 33,496 | -7.3% | 0.04% | -28.1% |
| Q2 2020 | $3,112,000 | -14.9% | 36,145 | -19.8% | 0.06% | -29.6% |
| Q1 2020 | $3,659,000 | +8.3% | 45,072 | +11.6% | 0.08% | +20.9% |
| Q4 2019 | $3,378,000 | -2.8% | 40,402 | +1.7% | 0.07% | -18.3% |
| Q3 2019 | $3,474,000 | +18.8% | 39,722 | +11.2% | 0.08% | +5.1% |
| Q2 2019 | $2,924,000 | -48.2% | 35,708 | -54.0% | 0.08% | -35.5% |
| Q1 2019 | $5,640,000 | – | 77,546 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |